X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8) 8
humans (7) 7
female (6) 6
hematology, oncology and palliative medicine (6) 6
lymphomas (6) 6
male (6) 6
middle aged (6) 6
oncology (6) 6
adult (5) 5
aged (5) 5
tumors (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
chemotherapy (4) 4
hodgkin disease - drug therapy (4) 4
stem cells (4) 4
transplantation (4) 4
treatment outcome (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
care and treatment (3) 3
disease (3) 3
disease-free survival (3) 3
drug administration schedule (3) 3
lymphoma (3) 3
medical prognosis (3) 3
positron-emission-tomography (3) 3
recurrence (3) 3
young adult (3) 3
administration, oral (2) 2
aged, 80 and over (2) 2
animals (2) 2
antibodies, monoclonal, murine-derived - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
cancer therapies (2) 2
cultures (2) 2
diseases (2) 2
dose-response relationship, drug (2) 2
doxorubicin - adverse effects (2) 2
drug dosages (2) 2
hodgkin disease - pathology (2) 2
hodgkin's disease (2) 2
immunoconjugates - administration & dosage (2) 2
immunoconjugates - adverse effects (2) 2
in-vitro (2) 2
kaplan-meier estimate (2) 2
leukemia (2) 2
maximum tolerated dose (2) 2
positron-emission tomography (2) 2
prognosis (2) 2
pyrimidines - adverse effects (2) 2
pyrimidines - therapeutic use (2) 2
randomized-trial (2) 2
relapse (2) 2
rituximab (2) 2
salvage therapy (2) 2
scaffolds (2) 2
stem cell transplantation (2) 2
survival rate (2) 2
therapy (2) 2
time factors (2) 2
tissue engineering (2) 2
toxicity (2) 2
adolescent (1) 1
algorithms (1) 1
analysis (1) 1
anemia - chemically induced (1) 1
angiogenesis inhibitors (1) 1
animals, newborn (1) 1
anthracyclines (1) 1
anti-cd20 monoclonal-antibody (1) 1
antibodies (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, murine-derived - administration & dosage (1) 1
antibodies, monoclonal, murine-derived - therapeutic use (1) 1
antigens, cd20 - drug effects (1) 1
antigens, cd20 - immunology (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
assay (1) 1
autografts (1) 1
b-cell (1) 1
b-cell lymphoma (1) 1
bacteria - chemistry (1) 1
bendamustine plus rituximab (1) 1
benzamides - administration & dosage (1) 1
benzamides - adverse effects (1) 1
benzamides - therapeutic use (1) 1
bildgebungsverfahren (1) 1
biochemistry & molecular biology (1) 1
biomarker (1) 1
biomarkers (1) 1
biomaterials (1) 1
biomedical applications (1) 1
biomedical materials (1) 1
bioreactor (1) 1
bioreactors (1) 1
bioreaktor (1) 1
biotechnology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 9, pp. 1283 - 1294
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 284 - 292
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Summary Background Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide,... 
Hematology, Oncology and Palliative Medicine | THERAPY | OLDER PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLASSIFICATION | RANDOMIZED CONTROLLED-TRIAL | TARGETING BTK | ELDERLY-PATIENTS | CHEMOTHERAPY | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 7, pp. 716 - 723
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 13, pp. 1222 - 1228
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1348 - 1356
Journal Article
Journal of Materials Science: Materials in Medicine, ISSN 0957-4530, 9/2012, Volume 23, Issue 9, pp. 2253 - 2266
Journal Article
Journal of Materials Chemistry, ISSN 0959-9428, 10/2012, Volume 22, Issue 41, pp. 2212 - 22112
A nanocomposite based on bacterial cellulose (BC) and type I collagen (COL) was evaluated for in vitro bone regeneration. BC membranes were modified by glycine... 
IN-VITRO | REGENERATION | MATERIALS SCIENCE, MULTIDISCIPLINARY | CROSS-LINKING | MEMBRANES | BIOMEDICAL APPLICATIONS | POLY-EPSILON-CAPROLACTONE | SCAFFOLDS | HYDROXYAPATITE | RAT CALVARIAL OSTEOBLASTS | COMPOSITE
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.